Delayed diagnosis of primary hyperaldosteronism

BMJ (Online)

Volumn 340, Issue 7760, 2010, Pages 1358-1360

  Grasko, Jonathan M ^a   Nguyen, Hieu H ^b   Glendenning, Paul ^a,c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMLODIPINE; FELODIPINE; HYDROCORTISONE; LISINOPRIL; POTASSIUM; PRAZOSIN; RENIN;

ABDOMEN; ADENOMA; ADRENAL GLAND; ADRENAL TUMOR; ADRENALECTOMY; ADULT; ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DELAYED DIAGNOSIS; DRUG WITHDRAWAL; ELECTIVE SURGERY; FEMALE; HISTOLOGY; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; HYPOKALEMIA; LAPAROSCOPIC SURGERY; LIFESTYLE MODIFICATION; MALE; PARATHYROID CELL; PATIENT REFERRAL; POSTOPERATIVE PERIOD; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRIMARY HYPERALDOSTERONISM; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; REVIEW; UNSPECIFIED SIDE EFFECT;

ADULT; ALDOSTERONE; CALCIUM CHANNEL BLOCKERS; DELAYED DIAGNOSIS; DIHYDROPYRIDINES; DRUG RESISTANCE; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; MALE; MIDDLE AGED; POTASSIUM; RENIN;

EID: 77953727828     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c2461     Document Type: Review

References (20)

1. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2009;94:3623-30. [Abstract/Free Full Text]
2. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007;66:607-18. [CrossRef][Medline]
3. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003;42:161-5.[Abstract/Free Full Text]
4. Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens 2006;20:129-36.[CrossRef][Web of Science][Medline]
5. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr Pract 2006;12:193-222.[Medline]
6. Fiad TM, Cunningham SK, Hayes FJ, McKenna TJ. Effects of nifedipine treatment on the reninangiotensin- aldosterone axis. J Clin Endocrinol Metab 1997;82:457-60.[Abstract/Free Full Text]
7. Brown MJ, Hopper RV. Calcium-channel blockade can mask the diagnosis of Conn's syndrome. Postgrad Med J 1999;75:235-6.[Abstract/Free Full Text]
8. Nadar S, Lip GY, Beevers DG. Primary hyperaldosteronism. Ann Clin Biochem 2003;40:439-52. [Abstract/Free Full Text]
9. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002;40:897-902. [Abstract/Free Full Text]
10. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-81.[Abstract/Free Full Text]
11. Lim PO, MacDonald TM. Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension. Clin Endocrinol 2003;59:427-30.[CrossRef][Medline]
12. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19.[Abstract/Free Full Text]
13. Glendenning P, Vasikaran SD. Surgically correctable hypertension. Pathology 2002;34:297-8. [CrossRef][Web of Science][Medline]
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.[Abstract/Free Full Text]
15. National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. www.heartfoundation.org.au/SiteCollectionDocuments/A-Hypert-Guidelines2008- 2009Update-FINAL.pdf.
16. Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 2005;90:72-8.[Abstract/Free Full Text]
17. Handrock R, Rao-Schymanski R, Klugbauer N, Hofmann F, Herzig S. Dihydropyridine enantiomers block recombinant L-type Ca2+ channels by two different mechanisms. J Physiol 1999;521:31-42. [Abstract/Free Full Text]
18. Yokoyama T, Shimamoto K, Iimura O. [Mechanism of inhibition of aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism]. Nippon Naibunpi Gakkai Zasshi 1995;71:1059-74.[Medline]
19. Gordon RD. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens 2004;22:251-5.[Web of Science][Medline]
20. Lezoche E, Guerrieri M, Crosta F, Paganini A, D'Ambrosio G, Lezoche G, et al. Perioperative results of 214 laparoscopic adrenalectomies by anterior transperitoneal approach. Surg Endosc 2008;22:522-6. [CrossRef][Web of Science][Medline] (Pubitemid 351238247)